Drugs / ChAdOx2 RabG
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04162600 | Jan 2020 → Jul 2024 | rabies | University of Oxford | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04270838 | Feb 2022 → Sep 2028 expected | rabies | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07168018 | Dec 2025 → Mar 2026 overdue | rabies | University of Oxford | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx2 RabG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07168018 ↗ |
| Modality | Vaccine | “a simian adenovirus-vectored rabies vaccine candidate” PMID 35907430 ↗ Jul 2022 |
| Route | Intramuscular | “ChAdOx2 RabG, administered as a single intramuscular dose” PMID 35907430 ↗ Jul 2022 |